Eastern Mediterranean region countries have a high prevalence rate of Helicobacter Pylori (H.Pylori) infection [
1]. Chronic infection of
H. pylori contributes to multiple diseases such as peptic ulcer disease and subsequent bleeding [
2‐
4], dyspepsia, gastric adenocarcinoma [
5], mucosa-associated lymphoid tissue (MALT) lymphoma [
6], idiopathic thrombocytopenic purpura [
7], and unexplained iron deficiency anaemia [
8]. World health organization has listed the H.Pylori infection as a class 1 carcinogen [
9]. Eradication of H.Pylori cures previous diseases and can decrease the risk of gastric cancer [
10]. Eradication rate of
H. pylori infection is declining globally due to increased antibiotic resistance particularly clarithromycin and levofloxacin [
11]. In the eastern Mediterranean area, the resistance to clarithromycin, metronidazole, levofloxacin, amoxicillin, and tetracycline were 29%, 61%, 23%, 14%, 10% respectively [
12]. Several researchers reviewed many therapeutic regimens including sequential, concomitant, and hybrid to find the best treatment protocol [
13]. The results of conventional triple therapy in Syria were disappointing [
14]. Currently tetracycline is unavailable in Syria, so we used doxycycline in the bismuth quadruple regimen [
15,
16]. Although tinidazole isn’t superior to metronidazole in treating Helicobacter Pylori infections [
17], we used tinidazole instead of metronidazole in both regimens, as
H. pylori had high metronidazole resistance rate [
18]. Metronidazole is a commonly overused drug in Syria, mainly prescribed for gynaecological and gastrointestinal diseases [
19] Besides, tinidazole (b.i.d) is more tolerable by patients. There is a lack of data about the efficacy of doxycycline-based quadruple regimen and levofloxacin-containing quadruple concomitant regimen in Syrian patients, we conducted this trial to evaluate the efficacy and report the eradication rate of these regimens according to Intention-to-treat analysis (ITT) and per-protocol analysis (PPA).